Medication evidence profile

Formoterol

Ask about Formoterol

Clinical overview

Formoterol has public medication-list entries in Yamada-ABS 2023 and GABS 2018. These are 2 separate source versions, each with its own evidence and definitions.

Source-specific scores

SourceScore
JARSNot listed
Yamada-ABS1
BAASNot listed
Swe-ABSNot listed
GABS0
KABSNot listed
CALSNot listed

How to read this: 0 means the source explicitly assigned zero. “Not listed” means the source did not provide a score for this medication. Scores from different scales are not averaged.

Other names used in the sources

Formoterol inhalative, formoterol *

How to interpret the evidence

2 of 7 public source versions contain an explicit medication-list entry for formoterol.

The recorded values differ across the source rows for formoterol. Scale methods, definitions, source eras, evidence types and identity handling can differ; the numbers alone do not establish the reason for this medication’s disagreement.

GABS 2018 explicitly records zero. Those recorded zeros remain different from a missing entry.

Source labels and provenance · 2 observations
  1. Yamada Pharmacological Anticholinergic Burden Scale 2023

    Source label: Formoterol. Published value: 1.
    Source version: YAMADA-ABS-2023
    Source location: RC4 source recovery; recovery_scope=primary_nonzero_complete
    Observation: YAMADA_ABS_2023_R0023; rating state: published_rating.

  2. German Anticholinergic Burden Score 2018

    Source label: Formoterol inhalative. Published value: 0.
    Source version: GABS-2018
    Source location: 12877_2018_929_MOESM1_ESM.docx Table S3 row 139
    Observation: GABS_2018_R0289; rating state: published_zero.

Dose, route, and formulation notes

GABS 2018 uses the source label “Formoterol inhalative”. This qualification remains attached to that row. GABS-2018

What this page does not establish

  • No medication-list entry is available here from JARS 2025, BAAS 2019, Swe-ABS 2023, KABS 2020 open validation supplement, and CALS 2022 Table 4. These gaps remain “Not listed”; no score is inferred from another source or from class membership.
  • No route inference unless present in the source label.
  • These source records do not estimate an individual’s probability of harm or establish whether to start, stop or change a medication. Ordinal source scores are not averaged into a UnifiedACB score.

References

  1. Yamada S, Mochizuki M, Chimoto J, Futokoro R, Kagota S, Shinozuka K. Development of a pharmacological evidence-based anticholinergic burden scale for medications commonly used in older adults. Geriatr Gerontol Int. 2023;23(7):558-564. doi:10.1111/ggi.14619. Open source
  2. Kiesel EK, Hopf YM, Drey M. An anticholinergic burden score for German prescribers: score development. BMC Geriatr. 2018;18(1):239. doi:10.1186/s12877-018-0929-6. Open source

Ask a follow-up

Go to your medication comparison · How UnifiedACB handles disagreement

Ask about this medication

Medication context: Formoterol

Ask about this medication